# VEC-162 Study in Adult Patients With Primary Insomnia

> **NCT00548340** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 322 (actual)

## Conditions studied

- Primary Insomnia

## Interventions

- **DRUG:** VEC-162 20 mg
- **DRUG:** Placebo
- **DRUG:** VEC-162 50 mg

## Key facts

- **NCT ID:** NCT00548340
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-06
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548340, "VEC-162 Study in Adult Patients With Primary Insomnia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00548340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*